Principal Secretary of the State Department of Medical Services, Harry Kimtai, had a meeting with Pat Garcia, CEO of Max Foundation.
They talked about the Ministry’s collaboration with the Max Foundation, which aims to make Imatinib and other cutting-edge molecules accessible to cancer patients at a number of healthcare facilities, including the Nairobi Hospital, MTRH, Nakuru, Mombasa, and Jaramogi Oginga Odinga Teaching and Referral Hospital.
This partnership exemplifies the Ministry’s steadfast commitment to expanding access to high-quality cancer care throughout Kenya and is motivated by the idea of universal health coverage. The PS took advantage of the chance to reaffirm the Ministry’s commitment to this crucial task.
Imatinib is a BCR-ABL tyrosine kinase inhibitor, which is a class of antineoplastic (anti-cancer) drugs. It is a form of chemotherapy that inhibits the development of cancer cells and stops them from replicating.
Certain forms of leukaemia (cancer that starts in the white blood cells), as well as other malignancies and conditions affecting the blood cells, are treated with imatinib.
